Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
KNOXVILLE, Tenn.–(BUSINESS WIRE)–May 21, 2014–
EDP Biotech Corporation, an in-vitro cancer diagnostics development company, today announced that its abstract “CA 11-19: A Tumor Marker for the Diagnosis of Colorectal Cancer” has been accepted for presentation at the 2014 ASCO (American Society of Clinical Oncology) meeting in Chicago being held on May 30 – June 3, 2014.
CA 11-19, the Company’s proprietary biomarker tradenamed ColoMarker™ (patent pending), is a serologic tumor marker for colorectal cancer that correctly identified 100% of 63 patients with Stage I-II colon cancers.
The abstract presents an analysis of the 670 colonoscopy confirmed patients including normal, benign GI diseases, polyps and colon cancer in a blinded IRB approved study. CA 11-19 demonstrated an overall sensitivity for colon cancer detection of 95% and a specificity of 80%. The test is highly sensitive for detection of early stage colorectal cancer. Diagnostically, a positive assay result increases the odds of finding colorectal cancer by a factor of five.
Dr. Bergein Overholt, lead author, commented, “CA 11-19 provides a blood test for colon cancer detection that is highly sensitive in early stages of the disease. Additional studies are underway and if they confirm the results, this test could dramatically change the way physicians approach colon cancer diagnosis and management.”
Abstract No. 3555
Author(s): Bergein F Overholt, Tommye Jordan, Donald J Wheeler, Herbert A. Fritsche; Gastrointestinal Associates, Knoxville, TN; EDP Biotech, Knoxville, TN; Statistical Processing Controls, Knoxville, TN; Fritsche Consulting Services, Houston, TX
The discovery and development of a new revolutionary proprietary biomarker, CA11-19, can provide patients and physicians with an easier method to detect colorectal cancer. This unique and proprietary biomarker is measured by a simple blood test called the ColoMarker™ test. Based on IRB studies, the ColoMarker™ test has shown promising results in detecting colorectal cancer in the early stages of the disease when it is most treatable.
ColoMarker™ is a blood test requiring no advance preparation by the patient such as fasting or colon cleansing. ColoMarker™ can be added easily to the panel of tests routinely performed on the patient’s blood as part of the patient’s annual physical.
About EDP Biotech Corporation
EDP Biotech is dedicated to the development and commercialization of innovative cancer diagnostics, including simple cost-effective and accurate ELISA based colon cancer technology. EDP Biotech has research, license or commercialization agreements with leading institutions, including GI associates and Covent Health. For more information on EDP Biotech, visit our website: http://www.edpbiotech.com.
Jeff Hooper, 865-584-0550